Fatty acid and proteomic signatures of circulating CD81 positive small extracellular vesicles define the disease stage in melanoma patients

Paolino, Giovanni; Huber, Veronica; Camerini, Serena; Casella, Marialuisa; Macone, Alberto; Bertuccini, Lucia; Iosi, Francesca; Moliterni, Elisa; Cecchetti, Serena; Ruspantini, Irene; Chiarotti, Flavia; Raggi, Carla; Biase, Antonella Di; Calvieri, Stefano; Mercuri, Santo Raffaele; Lugini, Luana; Federici, Cristina

doi:10.20944/preprints202105.0577.v1

Cited by 3 publications

(2 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The enrichment of MIA and S100B in exosomes of melanoma patients indicated their potential value as diagnostic and prognostic markers (Alegre et al, 2016). Different content of some proteins, such as CD14, PON1, PON3 and APOA5, was revealed in small EVs from plasma of melanoma patients at distinct stages (0-IV), suggesting their potential use as biomarkers to monitor the disease (Paolino et al, 2021).…”

Section: Cargo Findingsmentioning

confidence: 96%

“…A more refined method for capturing subpopulations of circulating EVs employs specific antibodies coupled to beads. For example, using immunocapture with anti-CD81 coated beads, not only proteins but also fatty acids have been profiled in plasmacirculating CD81-EVs showing an increase in fatty acid content in melanoma late stages compared to healthy donors (Paolino et al, 2021). Due to the systemic influence of tumor growth through soluble factors and vesicle secretion, tumor-derived vesicles in circulation are just a portion of the total EV content in the blood.…”

Section: Circulating Evs In Plasma Lymph and Other Fluidsmentioning

confidence: 99%

See 1 more Smart Citation

Extracellular vesicles and melanoma: New perspectives on tumor microenvironment and metastasis

Benito-Martín

Jasiulionis

García‐Silva

2023

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Secreted extracellular vesicles (EVs) are lipid bilayer particles without functional nucleus naturally released from cells which constitute an intercellular communication system. There is a broad spectrum of vesicles shed by cells based on their physical properties such as size (small EVs and large EVs), biogenesis, cargo and functions, which provide an increasingly heterogenous landscape. In addition, they are involved in multiple physiological and pathological processes. In cancer, EV release is opted by tumor cells as a beneficial process for tumor progression. Cutaneous melanoma is a cancer that originates from the melanocyte lineage and shows a favorable prognosis at early stages. However, when melanoma cells acquire invasive capacity, it constitutes the most aggressive and deadly skin cancer. In this context, extracellular vesicles have been shown their relevance in facilitating melanoma progression through the modulation of the microenvironment and metastatic spreading. In agreement with the melanosome secretory capacity of melanocytes, melanoma cells display an enhanced EV shedding activity that has contributed to the utility of melanoma models for unravelling EV cargo and functions within a cancer scenario. In this review, we provide an in-depth overview of the characteristics of melanoma-derived EVs and their role in melanoma progression highlighting key advances and remaining open questions in the field.

show abstract

Section: Cargo Findingsmentioning

confidence: 96%

Section: Circulating Evs In Plasma Lymph and Other Fluidsmentioning

confidence: 99%

Extracellular vesicles and melanoma: New perspectives on tumor microenvironment and metastasis

Benito-Martín

Jasiulionis

García‐Silva

2023

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

Liquid Biopsy in Cancer: Focus on Lymphoproliferative Disorders

Savino

Rigali

Giustini

et al. 2022

Cancers

View full text Add to dashboard Cite

Within the context of precision medicine, the scientific community is giving particular attention to early diagnosis and intervention, guided by non-invasive methodologies. Liquid biopsy (LBx) is a recent laboratory approach consisting of a non-invasive blood draw, which allows the detection of information about potential prognostic factors, or markers to be used for diagnostic purposes; it might also allow the clinician to establish a treatment regimen and predict a patient’s response. Since the discovery of circulating tumor cells (CTCs) in the nineteenth century, the possibility of integrating LBx into clinical practice has been explored, primarily because of its safeness and easy execution: indeed, compared to solid biopsy, sampling-related risks are less of a concern, and the quickness and repeatability of the process could help confirm a prompt diagnosis or to further corroborate the existence of a metastatic spreading of the disease. LBx’s usefulness has been consolidated in a narrow range of oncological settings, first of all, non-small cell lung carcinoma (NSCLC), and it is now gradually being assessed also in lymphoproliferative diseases, such as acute lymphocytic leukemia (ALL), B-cell lymphomas, and multiple myeloma. The present review aims to summarize LBx's overall characteristics (such as its advantages and flaws, collection and analysis methodologies, indications, and targets of the test), and to highlight the applications of this technique within the specific field of B-cell malignancies. The perspectives on how such a simple and convenient technique could improve hemato-oncological clinical practice are broadly encouraging, yet far from a complete integration in routine clinical settings.

show abstract

LincRNA01703 Facilitates CD81+ Exosome Secretion to Inhibit Lung Adenocarcinoma Metastasis via the Rab27a/SYTL1/CD81 Complex

Huang,

Guo,

Lin

et al. 2023

Cancers

View full text Add to dashboard Cite

Metastasis, a major cause of cancer-related mortality worldwide, frequently occurs early in the diagnosis of lung adenocarcinoma (LUAD). However, the precise molecular mechanisms governing the aggressive metastatic behavior of LUAD remain incompletely understood. In this study, we present compelling evidence indicating that the long noncoding RNA linc01703 is significantly downregulated in metastatic lung cancer cells. Intriguingly, in vivo experiments revealed that Linc01703 exerted a profound inhibitory effect on lung cancer metastasis without discernible impact on the in vitro proliferation or invasion capacities of LUAD cells. Mechanistically, Linc01703 enhanced the interaction between Rab27a, SYTL1, and CD81, consequently promoting the secretion of CD81+ exosomes. These exosomes, in turn, suppressed the infiltration of immune cells within the tumor microenvironment, thereby impeding LUAD metastasis. Importantly, our analysis of lung cancer tissues revealed a correlation between reduced CD81 expression and an unfavorable patient prognosis. Collectively, our findings suggest that Linc01703 functions as a metastasis suppressor by facilitating the secretion of CD81+ exosomes through the formation of the Rab27a/SYTL1/CD81 complex.

show abstract

Fatty acid and proteomic signatures of circulating CD81 positive small extracellular vesicles define the disease stage in melanoma patients

Cited by 3 publications

References 57 publications

Extracellular vesicles and melanoma: New perspectives on tumor microenvironment and metastasis

Extracellular vesicles and melanoma: New perspectives on tumor microenvironment and metastasis

Liquid Biopsy in Cancer: Focus on Lymphoproliferative Disorders

LincRNA01703 Facilitates CD81+ Exosome Secretion to Inhibit Lung Adenocarcinoma Metastasis via the Rab27a/SYTL1/CD81 Complex

Contact Info

Product

Resources

About